Trastuzumab in the management of early and advanced stage breast cancer.
Trastuzumab is a monoclonal humanized antibody that has revolutionized the treatment of patients with Her2-positive breast cancer. Already well established in advanced stage disease, the substance was recently introduced in the adjuvant setting, reducing disease recurrences by more than 50% and mortality by approximately one third. Trastuzumab is a rationally designed substance which binds to cancer cells expressing the targeted antigen, and, by different mechanisms, causes tumor cell degradation. However, only one third of patients have an initial response to trastuzumab therapy, and the majority of initial responders demonstrate disease progression within 1 year of treatment initiation. It is therefore necessary to gain further insight into mechanisms of resistance, and develop ways to overcome those. In this article, the role of trastuzumab in early and advanced stage breast cancer is reviewed. We discuss current understandings of the specific tumor biology of Her2-positive breast cancer, and review the mechanism of action of trastuzumab. Further, we try to highlight possible mechanisms of resistance.
Bartsch
Rupert
R
First Department of Medicine and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Wenzel
Catharina
C
Steger
Guenther G
GG
J Clin Oncol. 1996 Mar;14(3):737-44
8622019
Nature. 2003 Feb 13;421(6924):756-60
12610629
Mol Cancer Ther. 2002 Jul;1(9):707-17
12479367
Br J Cancer. 2004 Aug 16;91(4):639-43
15266327
J Clin Oncol. 2005 Apr 1;23(10):2162-71
15800309
Cancer Res. 2001 Jun 15;61(12):4892-900
11406568
Ann Pathol. 2003 Dec;23(6):617-22
15094603
J Clin Oncol. 2004 Jan 15;22(2):322-9
14722042
J Clin Oncol. 2007 May 20;25(15):2012-8
17513805
J Clin Oncol. 2003 Jan 1;21(1):46-53
12506169
Nat Med. 2000 Apr;6(4):443-6
10742152
J Clin Pathol. 2000 Dec;53(12):890-2
11265171
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
J Mol Cell Cardiol. 2003 Dec;35(12):1473-9
14654373
Science. 1987 Jan 9;235(4785):177-82
3798106
Radiother Oncol. 2006 Sep;80(3):313-7
16959347
Ann Oncol. 2001;12 Suppl 1:S21-2
11521716
J Clin Oncol. 2004 Mar 15;22(6):1063-70
15020607
Clin Cancer Res. 2004 Jul 1;10(13):4457-63
15240537
J Clin Oncol. 2005 Jun 1;23(16):3676-85
15738535
Oncogene. 1998 Oct 29;17(17):2235-49
9811454
Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37
12138395
Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84
7819273
Nat Clin Pract Oncol. 2006 May;3(5):269-80
16683005
J Cell Physiol. 2004 Sep;200(3):343-50
15254961
Nature. 2002 Jan 31;415(6871):530-6
11823860
Oncogene. 1994 Jul;9(7):1829-38
7911565
Biochem J. 1999 Dec 1;344 Pt 2:339-48
10567214
J Mol Diagn. 2004 Feb;6(1):42-51
14736826
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S
14734488
Cancer Res. 2004 Jun 1;64(11):3981-6
15173011
Cancer Res. 2002 Jul 15;62(14):4132-41
12124352
Clin Breast Cancer. 2003 Jun;4(2):120-5
12864940
Cancer. 2002 Oct 1;95(7):1592-600
12237930
Clin Breast Cancer. 2004 Jun;5(2):142-7
15245619
J Clin Oncol. 2003 Nov 1;21(21):3965-71
14507946
Int J Cancer. 1991 Nov 11;49(5):650-5
1682277
Int J Clin Oncol. 2006 Jun;11(3):199-208
16850126
J Clin Oncol. 2003 Aug 1;21(15):2889-95
12885806
Cancer Res. 2001 Jun 15;61(12):4744-9
11406546
Eur J Cancer. 2007 Feb;43(3):497-509
17223541
Oncogene. 1999 Apr 1;18(13):2241-51
10327070
Mol Cell Biol. 2001 Jun;21(12):3995-4004
11359907
Science. 1989 May 12;244(4905):707-12
2470152
Cancer Res. 2006 Feb 1;66(3):1640-7
16452223
Oncologist. 2002;7(5):410-7
12401903
J Clin Oncol. 1998 Aug;16(8):2659-71
9704716
Mol Cell Biol. 1988 Mar;8(3):1019-26
2897079
Anticancer Res. 2002 Jul-Aug;22(4):2485-90
12174949
Cancer Res. 1999 Mar 15;59(6):1347-55
10096569
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
J Clin Oncol. 2005 Jul 1;23(19):4265-74
15911866
Oncogene. 2000 Jul 20;19(31):3460-9
10918604
BMC Cancer. 2006 Mar 15;6:63
16539726
Eur J Cancer. 2004 Feb;40(3):379-82
14746856
N Engl J Med. 2006 Feb 23;354(8):809-20
16495393
Cancer. 1986 Aug 15;58(4):832-9
3755076
Cancer. 1992 Feb 15;69(4):972-80
1735089
Cancer Chemother Pharmacol. 2010 Jul;66(2):269-76
19904537
J Clin Oncol. 2006 Apr 20;24(12):1831-8
16549824
Nature. 1986 Jan 16-22;319(6050):226-30
3945311
Biochemistry. 2004 Dec 28;43(51):16243-53
15610018
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
J Clin Oncol. 1990 Jan;8(1):103-12
1967301
Breast Cancer Res Treat. 2007 May;102(3):375-81
17028979
Ann Oncol. 2006 Apr;17(4):630-6
16410363
Oncologist. 2006;11 Suppl 1:34-41
16971738
Exp Hematol. 1999 Oct;27(10):1533-41
10517495
J Clin Oncol. 2007 Sep 1;25(25):3853-8
17679724
Clin Cancer Res. 2004 Mar 1;10(5):1706-16
15014023
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
Nature. 2002 Mar 21;416(6878):279-80
11907566
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
Cancer Cell. 2004 Aug;6(2):117-27
15324695
N Engl J Med. 2002 Dec 19;347(25):1999-2009
12490681
J Clin Oncol. 2006 Sep 1;24(25):4107-15
16908934
J Cancer Res Clin Oncol. 2004 Jul;130(7):400-4
15168107
Cancer. 2003 Jun 15;97(12):2972-7
12784331
Endocr Relat Cancer. 2002 Jun;9(2):75-85
12121832
Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13
16736978
Biochem Pharmacol. 2001 Nov 15;62(10):1311-36
11709192
Oncologist. 2003;8(4):307-25
12897328
Clin Cancer Res. 2004 Sep 1;10(17):5650-5
15355889
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
J Clin Oncol. 2008 Apr 20;26(12):1993-9
18421051
Cancer Chemother Pharmacol. 2002 Mar;49(3):211-6
11935213
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
11752009
J Clin Oncol. 2006 Jun 20;24(18):2786-92
16782917